Larimar Therapeutics

Bull case

• Larimar Therapeutics is supported by a compelling root-cause thesis in Friedreich’s ataxia, as nomlabofusp is designed to restore frataxin directly and has shown sustained biomarker and clinical improvements, including 82% of patients reaching asymptomatic-carrier skin frataxin levels at six months and 100% by one year and 18 months.
• The regulatory setup also looks constructive: the company has completed the first rolling BLA module, expects the remaining modules in 2H26, and management said the pre-BLA feedback was supportive, with the FDA willing to consider frataxin as a novel surrogate endpoint and the exposure-response analysis as supportive.
• Financially, Larimar ended 1Q26 with $200.4M in cash, cash equivalents, and marketable securities, guiding runway into 2Q27, while the launch case is meaningful with modeled 2027 sales of $47.9M and peak annual sales above $1.1B by 2040E.

Bear case

Larimar Therapeutics is viewed negatively because its valuation remains highly contingent on a single asset, nomlabofusp, leaving the company exposed to binary clinical, regulatory, and commercial outcomes in Friedreich’s ataxia. Even with a $1.19B enterprise value and 70% probability of approval in the DCF, the thesis still depends on completing the rolling BLA filing, obtaining timely FDA approval, and then achieving meaningful traction against Biogen’s marketed Skyclarys and other emerging therapies. The company also faces manufacturing, IP, and financing risks, including possible medium-term equity dilution, which could pressure returns if capital needs rise before commercialization.